These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 9617977)

  • 1. Safety of abrupt discontinuation of fluoxetine: a randomized, placebo-controlled study.
    Zajecka J; Fawcett J; Amsterdam J; Quitkin F; Reimherr F; Rosenbaum J; Michelson D; Beasley C
    J Clin Psychopharmacol; 1998 Jun; 18(3):193-7. PubMed ID: 9617977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment.
    Judge R; Parry MG; Quail D; Jacobson JG
    Int Clin Psychopharmacol; 2002 Sep; 17(5):217-25. PubMed ID: 12177584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse events after the abrupt discontinuation of paroxetine.
    Dominguez RA; Goodnick PJ
    Pharmacotherapy; 1995; 15(6):778-80. PubMed ID: 8602387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial.
    Rosenbaum JF; Fava M; Hoog SL; Ascroft RC; Krebs WB
    Biol Psychiatry; 1998 Jul; 44(2):77-87. PubMed ID: 9646889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous administration of adenosine triphosphate and phosphocreatine combined with fluoxetine in major depressive disorder: protocol for a randomized, double-blind, placebo-controlled pilot study.
    Chen Y; Cao X; Zang W; Tan S; Ou CQ; Shen X; Gao T; Zhao L
    Trials; 2019 Jan; 20(1):34. PubMed ID: 30626424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis.
    Beasley CM; Koke SC; Nilsson ME; Gonzales JS
    Clin Ther; 2000 Nov; 22(11):1319-30. PubMed ID: 11117656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delirium Associated With Fluoxetine Discontinuation: A Case Report.
    Fan KY; Liu HC
    Clin Neuropharmacol; 2017; 40(3):152-153. PubMed ID: 28452902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression.
    Miner CM; Brown EB; Gonzales JS; Munir R
    J Clin Psychiatry; 2002 Mar; 63(3):232-40. PubMed ID: 11926723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial.
    Michelson D; Fava M; Amsterdam J; Apter J; Londborg P; Tamura R; Tepner RG
    Br J Psychiatry; 2000 Apr; 176():363-8. PubMed ID: 10827885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discontinuation symptoms and SSRIs.
    Pollock BG
    J Clin Psychiatry; 1998 Oct; 59(10):535-7. PubMed ID: 9818635
    [No Abstract]   [Full Text] [Related]  

  • 11. [Discontinuation of antidepressant serotonergic antidepressant].
    Andersen CL; Videbech P
    Ugeskr Laeger; 2010 Jan; 172(4):296-8. PubMed ID: 20105399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluoxetine tenth anniversary update: the progress continues.
    Stokes PE; Holtz A
    Clin Ther; 1997; 19(5):1135-250. PubMed ID: 9385500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases.
    Keller MB; Trivedi MH; Thase ME; Shelton RC; Kornstein SG; Nemeroff CB; Friedman ES; Gelenberg AJ; Kocsis JH; Dunner DL; Hirschfeld RM; Rothschild AJ; Ferguson JM; Schatzberg AF; Zajecka JM; Pedersen RD; Yan B; Ahmed S; Musgnung J; Ninan PT
    J Clin Psychiatry; 2007 Aug; 68(8):1246-56. PubMed ID: 17854250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study.
    Emslie GJ; Heiligenstein JH; Hoog SL; Wagner KD; Findling RL; McCracken JT; Nilsson ME; Jacobson JG
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1397-405. PubMed ID: 15502599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: a clinical investigation.
    Bogetto F; Bellino S; Revello RB; Patria L
    CNS Drugs; 2002; 16(4):273-83. PubMed ID: 11945110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluoxetine: new indication. Depression in children: too many uncertainties.
    Prescrire Int; 2008 Oct; 17(97):186-7. PubMed ID: 19534039
    [No Abstract]   [Full Text] [Related]  

  • 17. Venlafaxine extended-release: a review of its use in the management of major depression.
    Wellington K; Perry CM
    CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial.
    Michelson D; Allgulander C; Dantendorfer K; Knezevic A; Maierhofer D; Micev V; Paunovic VR; Timotijevic I; Sarkar N; Skoglund L; Pemberton SC
    Br J Psychiatry; 2001 Dec; 179():514-8. PubMed ID: 11731354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective serotonin reuptake inhibitor. Discontinuation syndrome.
    Finfgeld DL
    J Psychosoc Nurs Ment Health Serv; 2002 Dec; 40(12):14-8. PubMed ID: 12491870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delirium following abrupt discontinuation of fluoxetine.
    Blum D; Maldonado J; Meyer E; Lansberg M
    Clin Neurol Neurosurg; 2008 Jan; 110(1):69-70. PubMed ID: 17913343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.